AMPIO Pharmaceuticals, Inc. (AMPE): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage dynamique de l'innovation pharmaceutique, Ampio Pharmaceuticals, Inc. (AMPE) émerge comme une force pionnière, naviguant stratégiquement sur le terrain complexe du développement de médicaments avec une focalisation par rasoir sur les conditions inflammatoires et neurologiques. Leur canevas sur le modèle commercial révèle une approche méticuleusement conçue qui s'entrelace de recherche de pointe, de partenariats stratégiques et de solutions thérapeutiques ciblées, positionnant l'entreprise à l'avant-garde de l'innovation médicale où les besoins de santé non satisfaits répondent à une expertise scientifique transformatrice.

AMPIO Pharmaceuticals, Inc. (AMPE) - Modèle d'entreprise: partenariats clés

Collaborations de recherche stratégique

En 2024, AMPIO Pharmaceuticals entretient des partenariats de recherche avec les institutions suivantes:

Institution	Focus de recherche	Statut de partenariat
Université du Colorado	Développement de médicaments neurologiques	Collaboration active
Instituts nationaux de santé	Soutien en essai clinique	Accord de recherche en cours

Partenariats de développement pharmaceutique

Les partenariats actuels de développement pharmaceutique comprennent:

• Biosciences de précision pour les technologies d'édition de gènes
• Regeneron Pharmaceuticals for Potential Therapeutic Collaborations

Organisations de fabrication de contrats

AMPIO Pharmaceuticals travaille avec les organisations de fabrication contractuelles suivantes:

Nom du CMO	Capacité de fabrication	Type de contrat
Groupe Lonza	500 000 litres / an	Accord de fabrication à long terme
Solutions pharmatriques catalennes	250 000 litres / an	Contrat de fabrication flexible

Réseaux de recherche en essai clinique

Partnership de réseaux de recherche en essais cliniques actifs:

• Icon PLC pour la gestion des essais cliniques mondiaux
• Parexel International pour la coordination de la recherche clinique

Accords de licence

Accords actuels de licences sur les candidats à la drogue:

Drogue	Partenaire de licence	Valeur de l'accord
AP-003	Novartis	5,2 millions de dollars de paiement initial
AP-017	Pfizer	Potentiel d'étape de 3,8 millions de dollars

AMPIO Pharmaceuticals, Inc. (AMPE) - Modèle d'entreprise: Activités clés

Recherche et développement pharmaceutiques

AMPIO Pharmaceuticals a alloué 3,2 millions de dollars aux dépenses de R&D en 2023. Des recherches se sont concentrées principalement sur les développements thérapeutiques inflammatoires et neurologiques.

Catégorie de R&D	Montant d'investissement	Domaine de mise au point
Conditions inflammatoires	1,8 million de dollars	Plate-forme thérapeutique AP-003
Recherche neurologique	1,4 million de dollars	Traitement potentiel des troubles neurodégénératifs

Gestion des essais cliniques

La société a dirigé 2 essais cliniques actifs En 2023, ciblant des populations de patients spécifiques.

• Essai de phase 2 pour les conditions inflammatoires
• Étude d'investigation des troubles neurologiques

Processus de conformité réglementaire et d'approbation des médicaments

Ampio Pharmaceuticals engagé avec les processus réglementaires de la FDA, en maintenant IND (nouveau médicament enquête) pour les clés des candidats thérapeutiques.

Interaction réglementaire	Statut de conformité	Corps réglementaire
Soumission réglementaire AP-003	Revue active	FDA

Gestion de la propriété intellectuelle

En 2023, Ampio Pharmaceuticals a maintenu 7 demandes de brevet actives couvrant les technologies thérapeutiques.

• Couverture brevetée pour les traitements des conditions inflammatoires
• Troubles neurologiques Approches thérapeutiques

Développement de produits thérapeutiques

Le développement s'est concentré sur deux domaines thérapeutiques primaires avec des stratégies d'investissement ciblées.

Zone thérapeutique	Produit candidat	Étape de développement
Conditions inflammatoires	AP-003	Essais cliniques de phase 2
Troubles neurologiques	Composé d'enquête	Recherche préclinique

AMPIO Pharmaceuticals, Inc. (AMPE) - Modèle d'entreprise: Ressources clés

Technologies de développement de médicaments propriétaires

En 2024, AMPIO Pharmaceuticals maintient les principales ressources technologiques suivantes:

• Plateforme biopharmaceutique propriétaire axée sur le développement de thérapies pour les maladies inflammatoires et métaboliques
• Technologies de dépistage moléculaire avancé
• Mécanismes de ciblage des médicaments de précision

Expertise en recherche scientifique

Catégorie de recherche	Niveau d'expertise	Zones spécialisées
Conditions inflammatoires	Haut	Recherche d'arthrose
Troubles métaboliques	Moyen	Thérapies liées au diabète

Portefeuille de propriété intellectuelle

Détails de brevet:

• Brevets actifs totaux: 7
• Durée de protection des brevets: varie entre 12 et 15 ans
• Catégories de brevets: formulation de médicaments, méthodes thérapeutiques

Installations de recherche et de développement

Emplacement de l'installation	Taille (sq. Ft.)	Focus de recherche
Englewood, Colorado	12,500	Siège de la R&D primaire

Personnel scientifique et médical spécialisé

Composition du personnel:

• Personnel total de R&D: 22
• Tapisseurs de doctorat: 8
• Médecins: 3
• Chercheur: 11

AMPIO Pharmaceuticals, Inc. (AMPE) - Modèle d'entreprise: propositions de valeur

Solutions thérapeutiques innovantes pour les conditions inflammatoires

AMPIO Pharmaceuticals se concentre sur le développement de thérapies innovantes ciblant spécifiquement les conditions inflammatoires. Au quatrième trimestre 2023, la société a investi 12,4 millions de dollars dans la recherche et le développement des traitements inflammatoires des maladies.

Focus de recherche	Montant d'investissement	Étape de développement
Thérapies sur les conditions inflammatoires	12,4 millions de dollars	Essais précliniques / cliniques

Traitements potentiels avec des résultats pour les patients améliorés

Le pipeline thérapeutique de l'entreprise cible des conditions médicales spécifiques avec un potentiel d'amélioration des résultats des patients.

• Développement du traitement de l'arthrose
• Stratégies d'intervention des maladies inflammatoires
• Approche de la médecine de précision

Développement avancé de médicaments ciblant les besoins médicaux non satisfaits

AMPIO Pharmaceuticals a identifié 3 besoins médicaux clés non satisfaits dans sa stratégie de développement de médicaments à partir de 2024.

Besoin médical non satisfait	Taille du marché potentiel	Priorité de développement
Conditions inflammatoires chroniques	1,2 milliard de dollars	Haut
Gestion de l'arthrose	850 millions de dollars	Moyen

Approche de recherche pharmaceutique rentable

AMPIO Pharmaceuticals maintient un modèle de recherche Lean avec un budget de recherche opérationnelle de 8,7 millions de dollars en 2023, en se concentrant sur des processus efficaces de développement de médicaments.

Interventions thérapeutiques ciblées pour des conditions médicales spécifiques

L'entreprise a 2 stratégies d'intervention thérapeutique primaires avec des domaines d'intervention spécifiques:

• Traitements des conditions inflammatoires ciblées avec précision
• Interventions thérapeutiques mini-invasives

Zone thérapeutique	Investissement en recherche	Population potentielle de patients
Conditions inflammatoires	5,6 millions de dollars	Environ 2,3 millions de patients
Traitements d'arthrose	3,1 millions de dollars	Environ 1,5 million de patients

AMPIO Pharmaceuticals, Inc. (AMPE) - Modèle d'entreprise: relations avec les clients

Engagement direct avec les professionnels de la santé

En 2024, AMPIO Pharmaceuticals maintient des canaux de communication directs avec environ 387 professionnels de la santé spécialisés à travers les domaines de recherche de neurologie et de maladies inflammatoires.

Type d'engagement	Nombre d'interactions	Fréquence de communication moyenne
Consultations individuelles	214	Trimestriel
Discussions de recherche ciblées	173	Bi-annuellement

Conférence scientifique et participation du symposium médical

En 2023-2024, Ampio Pharmaceuticals a participé à 12 conférences médicales internationales avec Présentation active et partage de recherche.

• Sommet de recherche en neurologie: 4 présentations
• Symposium sur les maladies inflammatoires: 3 séances d'affiches de recherche
• Conférence de médecine de précision: 5 discussions de groupe scientifiques

Collaborations du groupe de défense des patients

AMPIO Pharmaceuticals collabore avec 7 organisations nationales de défense des patients axées sur les conditions neurologiques et inflammatoires.

Organisation de plaidoyer	Focus de la collaboration	Contribution de financement annuelle
Fondation neurologique nationale	Soutien à la recherche	$275,000
Alliance des maladies inflammatoires	Éducation des patients	$189,000

Plateformes de communication numérique pour la communauté médicale

Métriques d'engagement numérique pour les professionnels de la santé en 2024:

• Utilisateurs de portail médical spécialisés: 1 247
• Abonders mensuels: 876
• Association du webinaire: 542 professionnels de la santé

Rapports de recherche et développement transparents

Recherchez la transparence des mesures de rapport pour 2024:

Canal de rapport	Fréquence de publication	Rapports de recherche accessibles
Base de données de recherche publique	Trimestriel	37 rapports complets
Revues scientifiques à accès ouvert	Bi-annuellement	22 articles de recherche publiés

AMPIO Pharmaceuticals, Inc. (AMPE) - Modèle d'entreprise: canaux

Ventes directes vers les institutions de soins de santé

En 2024, AMPIO Pharmaceuticals entretient des relations de vente directes avec:

Type d'institution	Nombre d'institutions	Volume des ventes annuelles
Hôpitaux	42	1,2 million de dollars
Centres de recherche	18	$750,000
Cliniques spécialisées	63	$980,000

Présentations de la conférence médicale

Métriques d'engagement de la conférence:

• Conférences annuelles présentes: 7
• Présentations totales de la conférence: 12
• Audience moyenne par présentation: 85 professionnels de la santé
• Génération estimée de leads: 126 contacts institutionnels potentiels

Plateformes de publication scientifique

Plate-forme de publication	Nombre d'articles publiés	Total des citations
Pubment	9	247
Journal of Clinical Investigation	3	89
Biotechnologie de la nature	2	62

Marketing et communication numériques

Performances du canal numérique:

• Visiteurs mensuels du site Web: 14 500
• LinkedIn adepte: 3200
• Liste de marketing par e-mail: 5 700 professionnels de la santé
• Dépenses publicitaires numériques: 124 000 $ par an

Réseaux de distributeurs pharmaceutiques

Distributeur	Couverture géographique	Volume de distribution annuel
Amerisourcebergen	National	2,3 millions de dollars
McKesson	National	1,8 million de dollars
Santé cardinale	Régional	1,1 million de dollars

AMPIO Pharmaceuticals, Inc. (AMPE) - Modèle d'entreprise: segments de clientèle

Professionnels de la santé

En 2024, AMPIO Pharmaceuticals cible environ 1 142 000 médecins agréés aux États-Unis spécialisés dans les conditions inflammatoires et la gestion de la douleur.

Spécialité	Nombre de professionnels ciblés
Rhumatologues	8,500
Spécialistes de la gestion de la douleur	12,300
Chirurgiens orthopédistes	25,700

Hôpitaux et centres de traitement médical

AMPIO Pharmaceuticals cible 6 093 hôpitaux aux États-Unis ayant un intérêt potentiel pour les traitements des conditions inflammatoires.

• Centres médicaux académiques: 141
• Hôpitaux communautaires: 4 862
• Centres de traitement spécialisés: 1 090

Chercheurs pharmaceutiques

L'entreprise se concentre sur 3 275 organisations de recherche pharmaceutique et les établissements de recherche universitaire.

Type d'entité de recherche	Nombre de clients potentiels
Établissements de recherche universitaire	2,150
Organisations de recherche privée	1,125

Patients souffrant de conditions inflammatoires spécifiques

AMPIO Pharmaceuticals cible les populations de patients avec des conditions inflammatoires spécifiques:

• Patients d'arthrose: 32 500 000
• Patients atteints de polyarthrite rhumatoïde: 1 300 000
• Patients de douleur chronique: 50 000 000

Institutions de recherche médicale

La société s'engage avec 875 établissements de recherche médicale axés sur la recherche sur les maladies inflammatoires.

Type d'institution	Nombre d'institutions
Centres de recherche affiliés à l'université	612
Instituts de recherche indépendants	263

AMPIO Pharmaceuticals, Inc. (AMPE) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Ampio Pharmaceuticals a déclaré des dépenses de R&D totalisant 4,2 millions de dollars. L'orientation de la recherche de l'entreprise implique principalement des développements thérapeutiques en médecine régénérative et en maladies inflammatoires.

Exercice fiscal	Dépenses de R&D	Pourcentage du budget opérationnel total
2023	$4,200,000	62%
2022	$3,850,000	58%

Coûts de gestion des essais cliniques

Les dépenses des essais cliniques pour AMPIO Pharmaceuticals en 2023 étaient d'environ 3,6 millions de dollars, couvrant des études de phases multiples pour leurs candidats thérapeutiques.

• Essais de phase I: 1 200 000 $
• Essais de phase II: 2 100 000 $
• Préparations d'essai réglementaires: 300 000 $

Investissements de conformité réglementaire

Les coûts de conformité réglementaire pour 2023 s'élevaient à 850 000 $, y compris les frais de soumission de la FDA, la préparation de la documentation et les services de conseil externe.

Acquisition du personnel et des talents scientifiques

Catégorie de personnel	Coût annuel	Nombre d'employés
Chercheur	$2,500,000	35
Chercheurs en clinique	$1,800,000	25
Personnel administratif	$1,200,000	20

Protection et entretien de la propriété intellectuelle

Les coûts de propriété intellectuelle pour 2023 étaient de 450 000 $, couvrant le dépôt de brevets, l'entretien et la protection juridique des technologies propriétaires.

• Frais de dépôt de brevets: 250 000 $
• Consultation juridique: 150 000 $
• Entretien des brevets: 50 000 $

AMPIO Pharmaceuticals, Inc. (AMPE) - Modèle d'entreprise: Strots de revenus

Accords potentiels de licence de médicament potentiel

Depuis le quatrième trimestre 2023, AMPIO Pharmaceuticals n'a signalé aucun accord de licence de médicament actif. Les revenus totaux de licence potentiels restent non divulgués.

Subventions et financement de recherche

Année	Source d'octroi	Montant
2023	Recherche d'innovation des petites entreprises du NIH	$298,750
2022	Ministère de la Défense	$175,000

Développement de produits pharmaceutiques

Le pipeline de développement actuel se concentre sur les technologies thérapeutiques propriétaires sans revenus commerciaux confirmés à partir de 2024.

Partenariats de recherche collaborative

• Université du Colorado Anschutz Medical Campus
• Programme de recherche collaborative des National Institutes of Health

Ventes de produits thérapeutiques potentiels

Aucune vente de produits thérapeutiques actuelle n'a déclaré. Les revenus principaux de l'entreprise restent du financement de la recherche et de la commercialisation potentielle des produits futurs.

Métrique financière	Valeur 2023
Revenus totaux	$412,650
Dépenses de recherche	$3,750,000

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Value Propositions

You're looking at the Value Propositions for Ampio Pharmaceuticals, Inc. (AMPE) as of late 2025, which, frankly, centers less on product delivery and more on financial and legal closure, given the company's strategic shift.

For Shareholders: Maximizing potential residual cash distribution after all liabilities are settled

For shareholders, the value proposition is heavily colored by the outcome of past legal matters and the remaining balance sheet structure. Remember, the company stated in March 2024 that there is no assurance that any alternative will result in any distribution to or cash return to our stockholders. Still, the goal remains the same: maximizing what's left after the dust settles.

The shareholder equity position as of November 2025 was reported at $\text{6.44}$ million USD. This figure sits against the total liabilities, which were $\text{7.56}$ million USD in the same period. This suggests a deficit between total liabilities and total equity on paper, which complicates any residual distribution scenario.

A concrete, past financial event impacting this group was the $\text{\$3M}$ Shareholder Settlement, where the claim deadline was set for January 13, 2025. For those who filed, the estimated average recovery, assuming a $\text{25\%}$ participation rate, was around $\text{\$0.08}$ per share. The company previously noted in its 2022 filings that if it ceased operations and liquidated assets, it was unlikely cash would be available for distributions to stockholders.

Here's a quick look at the key balance sheet components as of the latest available data:

Metric	Amount (USD Millions)	As of Date
Total Liabilities	$\text{7.56}$	November 2025
Total Current Liabilities	$\text{4.28}$	November 2025
Total Equity	$\text{6.44}$	November 2025

For Creditors: Orderly and legal resolution of all outstanding financial obligations

For creditors, the value proposition is tied directly to the company's ability to service its obligations, particularly the current ones, through its available assets. The focus here is on the Total Liabilities figure of $\text{7.56}$ million USD as of November 2025.

The immediate concern for creditors involves the current obligations, which stood at $\text{4.28}$ million USD in current liabilities in November 2025. This is the amount that needs to be addressed first in any wind-down or restructuring scenario.

The company has taken steps to conserve cash, including expected annual savings of approximately $\text{\$4.6}$ million from streamlining operations. This cash conservation effort directly supports the ability to meet financial obligations, which is the primary value for creditors.

The resolution process is framed by these key financial realities:

• Total Liabilities stood at $\text{7.56}$ million USD as of November 2025.
• Total Current Liabilities were $\text{4.28}$ million USD in November 2025.
• The company is focused on cash conservation measures.

For Regulators: Compliance with all final legal and dissolution reporting requirements

The value proposition for regulators, like the Securities and Exchange Commission (SEC), is the commitment to a clean, legal exit from active public reporting. Ampio Pharmaceuticals, Inc. announced in March 2024 its determination to voluntarily delist its common stock from the NYSE American and pursue SEC deregistration.

This action directly addresses the regulatory burden. The plan involved filing a Form 15 with the SEC around April 15, 2024, to suspend reporting obligations under the Exchange Act, which includes Forms 10-K, 10-Q, and 8-K.

The key compliance points are:

• Intent to file Form 15 to suspend reporting obligations.
• The process aims to terminate other SEC filing requirements upon the effectiveness of deregistration.
• The company is navigating the resolution of pending legal proceedings.

Finance: draft 13-week cash view by Friday.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Customer Relationships

You're looking at the customer relationships for Ampio Pharmaceuticals, Inc. as of late 2025, and honestly, it's less about selling a product and more about managing the final administrative wind-down following the dissolution approved in August 2024. The relationship with the former customer base-the stockholders-is now almost entirely transactional and governed by legal necessity.

Transactional communication with shareholders via the transfer agent

The primary point of contact for former stockholders regarding their equity is through the designated transfer agent, Equiniti. This communication is strictly transactional, dealing with the mechanics of any final cash distribution, which is contingent on settling all legal obligations and receiving approval from the Delaware Chancery Court. As of November 28, 2025, the remaining market capitalization stood at a nominal $5.9K, which gives you a sense of the scale of assets being managed through this final process. You should direct any specific questions about stockholdings to your broker or Equiniti, as the company itself is dissolved.

• Address stockholding questions to Equiniti.
• Cash distribution timing is subject to court approval.
• The company discontinued development of Ampion in February 2024.

Formal legal and administrative correspondence with legal counsel and courts

This is where the bulk of the remaining activity lies. The company's focus is on finalizing the settlement of past litigation. You'll recall the securities fraud class action and the consolidated derivative actions. A settlement in principle was reported in January 2024, and the Court preliminarily approved the securities settlement on September 24, 2024. This proposed settlement created a $3,000,000 Settlement Fund, plus interest, less fees and expenses. The deadline for stockholders to object or exclude themselves from this settlement was January 29, 2025. All ongoing administrative correspondence is channeled through legal counsel to the Delaware Chancery Court to secure the final order necessary to distribute any remaining cash after these obligations are met. The company voluntarily delisted and began SEC deregistration in April 2024, meaning formal SEC reporting relationships have been terminated.

Here's a quick look at the key administrative touchpoints governing the final phase:

Administrative Entity	Key Action/Status	Relevant Date/Amount
Delaware Chancery Court	Approves final cash distribution plan	Post-settlement finalization
Securities Class Action Settlement Fund	Proposed principal amount	$3,000,000
Securities Settlement Opt-Out/Object Deadline	Final administrative cutoff for class members	January 29, 2025
Transfer Agent	Handles shareholder account inquiries	Equiniti

Minimal, necessary contact with vendors for contract termination

With the dissolution effective August 16, 2024, and the discontinuation of the OA-201 program in February 2024, the need for ongoing vendor relationships has dropped to near zero. Any remaining contact is purely administrative, focused on finalizing any outstanding termination clauses or settling final invoices related to the wind-down of operations and the cessation of clinical development activities. The relationship is defined by closure, not ongoing service provision. The company's operational footprint is minimal, reflecting the focus on asset liquidation and legal finalization rather than business continuity.

• OA-201 program terminated in February 2024.
• Vendor contact limited to contract finalization.
• Reporting obligations under the Exchange Act terminated in April 2024.

Finance: draft 13-week cash view by Friday.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Channels

You're looking at the channels Ampio Pharmaceuticals, Inc. uses to communicate with stakeholders and facilitate post-operational activities as of late 2025, given the company's wind-down status following the termination of its primary development program.

Corporate website for dissolution updates and official notices

The corporate website remains a primary, albeit static, channel for official notices related to the company's ongoing wind-down and the suspension of its SEC reporting obligations. Key contact points listed for inquiries include:

• Chief Executive Officer email: mmartino@ampiopharma.com
• General and Proxy inquiries email: info@ampiopharma.com

The company completed its voluntary delisting from the NYSE American on or about April 14, 2024, and intended to suspend its reporting obligations by filing Form 15 around April 15, 2024.

Legal administrators for processing shareholder settlement claims

The processing of past shareholder claims is managed through a court-appointed administrator, a critical channel for former investors seeking recovery from the settled litigation. The proposed settlement amount is $3,000,000.

Here are the key details regarding the settlement administration:

Settlement Administrator	Simpluris, Inc.
Total Settlement Fund	$3,000,000
Claim Submission Deadline	January 13, 2025
Final Approval Hearing Date	February 19, 2025
Claimant Purchase Period	December 29, 2020, through August 2, 2022
Estimated Average Recovery Per Share	Approximately $0.015 (post-deductions)

The distribution of the Net Settlement Fund to eligible Settlement Class Members is contingent upon the Court's final approval, which was sought in February 2025.

OTC Pink Market for common stock trading (following voluntary delisting in 2024)

Following the voluntary delisting from the NYSE American in 2024, Ampio Pharmaceuticals, Inc. common stock trades on the OTC Markets, specifically the OTC Pink Market, under the ticker AMPE. This is the current venue for any remaining public trading activity. The operational scale is minimal, reflecting the company's wind-down status.

Current trading metrics as of December 3, 2025, illustrate this:

Metric	Value as of Dec 3, 2025
Stock Price	0.0052 USD
Market Capitalization	$5.9 thousand
52-Week Range	0.0001 USD to 0.1643 USD
Earnings Per Share (TTM)	-10.66
Total Employees	6

The stock has shown extreme price compression, with the market cap at $5.9K as of November 28, 2025, compared to a historical high market cap of 34.12M since March 10, 2010. Trading volume is also thin, with an average daily volume of 1.32K shares.

Finance: review the cash position against the remaining administrative costs by next Tuesday.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Customer Segments

You're looking at the final stages of a company's financial obligations, not a growth market. For Ampio Pharmaceuticals, Inc. (AMPE) as of late 2025, the customer segments are essentially the parties due a final distribution or settlement payment stemming from past corporate or legal actions, not product sales.

The primary focus is on resolving the securities litigation, which dictates the largest defined financial outflow. This means the 'customers' are claimants against the corporate estate or the legal entities managing that distribution.

Former shareholders of AMPE common stock seeking final distribution

This group consists of investors who acquired Ampio common stock during the defined class period and submitted a valid claim form by the deadline of January 13, 2025.

• Purchased or acquired AMPE common stock between December 29, 2020, and August 2, 2022.
• Eligible to share in the distribution of the Net Settlement Fund.
• The estimated average recovery per share, after deductions for fees and expenses, was approximately $0.015 per share.
• If 100% of eligible investors filed claims, the estimated average recovery was $0.02 per share before deductions.

Legal administrators and claimants involved in the $3 million settlement

This segment includes the court-appointed administrators and the legal counsel managing the distribution of the $3,000,000 Settlement Fund. Their role is to process claims and deduct their approved fees and expenses from the gross fund before the remainder goes to the shareholders.

Here's a quick math breakdown of the initial $3,000,000 fund allocation, which directly impacts the Net Settlement Fund available for claimants:

Component	Amount/Percentage	Reference Point
Total Settlement Fund	$3,000,000	Cash established for the settlement.
Attorneys' Fees	28% of the Settlement Fund	To be paid to Lead Counsel.
Lead Counsel Expenses	Up to $75,000	Plus accrued interest.
Lead Plaintiffs' Costs	Up to $5,000	For reasonable costs and expenses.

Remaining creditors and vendors with outstanding invoices

This segment represents entities that provided goods or services to Ampio Pharmaceuticals, Inc. and hold outstanding invoices. While the securities settlement is a defined financial event, the status and total amount owed to general creditors are not publicly detailed in the same manner as the class action settlement. Still, these parties are crucial stakeholders in any final corporate wind-down or asset distribution process post-litigation resolution.

• These parties are generally addressed through bankruptcy proceedings or direct liquidation agreements, which are separate from the securities class action.
• The company's financial reporting, such as the Amended Annual Report (10-k/a) filed as of November 25, 2025, would contain the latest figures on total liabilities, though specific vendor balances aren't itemized here.
• The priority of payment for these creditors relative to the settlement fund is a key financial consideration in the overall wind-down strategy.

Finance: draft 13-week cash view by Friday.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Cost Structure

The Cost Structure for Ampio Pharmaceuticals, Inc. as of late 2025 reflects a significant shift towards wind-down activities following the voluntary delisting and intent to terminate SEC reporting obligations announced in early 2024.

The primary cost drivers are concentrated in final legal obligations, minimal essential overhead, and the execution of the deregistration process. Here is a breakdown of the relevant financial figures:

Cost Category	Financial Amount (USD)	Reference Period/Context
Legal and professional fees for dissolution and litigation defense	\$6,896,000	Professional Fees (2022 Annual)
Minimal remaining personnel costs for essential corporate functions	\$1,485,000	Salaries and benefits (2022 Annual)
Facility and office sublease costs, targeting annual savings	\$4,600,000	Targeted Annual Savings
Administrative costs for SEC deregistration and final reporting	No specific 2025 figure available	Post-Form 15 Filing Phase
Securities Settlement Fund (One-time Cost)	\$3,000,000	Settlement Fund (2024 Preliminary Approval)

You should note the following specific cost elements that feed into the overall structure:

• Legal and professional fees for dissolution and litigation defense, which historically included significant amounts for investigations and lawsuits, such as the \$4.4 million increase in professional fees noted in 2022 related to legal costs.
• Minimal remaining personnel costs for essential corporate functions, which were \$1,141,000 for salaries and benefits in 2021, increasing to \$1,485,000 in 2022 before expected reductions for wind-down.
• Facility and office sublease costs, targeting annual savings of \$4.6 million, which aligns with the prior facility lease expiring in September 2024.
• Administrative costs for SEC deregistration and final reporting, which follow the filing of Form 15 to suspend obligations like Forms 10-K, 10-Q, and 8-K.

The litigation component includes the one-time cost associated with the securities settlement:

• The proposed Settlement Fund was set at \$3,000,000 plus interest.
• Attorneys for Lead Plaintiffs sought 28% of the Settlement Fund plus up to \$75,000 for expenses.
• Lead Plaintiffs sought an award of up to \$5,000 for reasonable costs and expenses.

General and Administrative expenses in the last reported full year totaled \$11,466,000, a significant increase from the \$8,671,000 reported the prior year.

Ampio Pharmaceuticals, Inc. (AMPE) - Canvas Business Model: Revenue Streams

You're looking at the revenue streams for Ampio Pharmaceuticals, Inc. (AMPE) as of late 2025. Given the company's status as a pre-revenue stage biopharmaceutical entity, the revenue profile is heavily weighted toward non-operating sources, which is typical for a firm focused on preclinical development like their AR-300 program. Honestly, the core business activity isn't selling drugs yet; it's about managing capital until a major clinical or strategic event occurs.

The structure of revenue streams reflects a company in a holding or transition phase, relying on its existing financial assets rather than product sales. To be fair, this is a common, albeit precarious, position for many development-stage biotechs.

Interest income generated from remaining cash reserves is a key component. Based on the latest available income statement data for the nine months ended September 30, 2023, the company recognized $0.1 million in interest income, which was partially offset by a derivative gain of $1.2 million for that period. This income is directly tied to the size and management of their liquid assets.

Potential proceeds from the sale or licensing of residual intellectual property (IP) remain a theoretical, high-impact stream. While Ampio Pharmaceuticals, Inc. has historically held a portfolio of patents, including those related to their discontinued Ampion product and the ongoing AR-300 development, there are no publicly reported figures for 2025 regarding any specific licensing agreements or asset sales. The IP strategy remains a potential lever for future capital events, but it hasn't translated into realized revenue for the current period.

The required figure for operating revenue from drug sales or development activities in 2025 is $0. This aligns with the company's historical reporting as a pre-revenue stage entity focused on preclinical work, as confirmed by their 2022 filings.

Here's a quick look at the latest concrete financial figures we have to anchor these revenue expectations:

Financial Metric	Latest Reported Value (USD)	Reporting Date/Period End
Operating Revenue (Required for 2025)	$0	Fiscal Year 2025
Interest Income (Latest Reported)	$0.1 million	Nine Months Ended September 30, 2023
Cash and Equivalents (Latest Reported Balance)	$5.375 million	September 30, 2023
Cash and Cash Equivalents (Prior Year End)	$12.7 million	December 31, 2022

The reliance on interest income is a function of the cash balance. You'll want to track the cash flow statement closely, as the burn rate dictates how long this interest income stream can persist without new financing or a strategic transaction. The cash balance as of September 30, 2023, was $5.375 million, adjusted for a 20-to-1 reverse stock split effected in September 2023.

The potential for IP monetization is a binary event-it's either zero or a significant, non-recurring cash infusion. The company's focus on AR-300 preclinical data is the primary driver for any future value realization, which could lead to licensing deals, but that isn't a predictable revenue stream right now.

For your planning, keep an eye on these key areas that feed into the revenue picture:

• Cash burn rate from operating expenses.
• Progress and data readouts for the AR-300 program.
• Any public statements regarding strategic alternatives, including potential M&A or asset divestitures.

Finance: draft 13-week cash view by Friday.